Compare WNC & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WNC | EVMN |
|---|---|---|
| Founded | 1985 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 511.7M | 474.7M |
| IPO Year | 2009 | 2025 |
| Metric | WNC | EVMN |
|---|---|---|
| Price | $12.82 | $7.06 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | $22.50 | ★ $24.13 |
| AVG Volume (30 Days) | 601.0K | ★ 692.3K |
| Earning Date | 10-29-2026 | 11-07-2026 |
| Dividend Yield | ★ 2.60% | N/A |
| EPS Growth | ★ 179.22 | 75.23 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,027,489,000.00 | $13,000,000.00 |
| Revenue This Year | $4.32 | N/A |
| Revenue Next Year | $28.30 | $40.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 8.81 | ★ 85.71 |
| 52 Week Low | $6.63 | $8.11 |
| 52 Week High | $14.47 | $33.20 |
| Indicator | WNC | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 47.84 | 24.88 |
| Support Level | $11.58 | N/A |
| Resistance Level | $13.02 | $13.35 |
| Average True Range (ATR) | 0.60 | 0.47 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 50.56 | 2.78 |
Wabash National Corp operates as the innovation leader of connected solutions for the transportation, logistics, and distribution industries. The Company manages its business in two operating and reportable segments: Transportation Solutions and Parts & Services. It designs and manufactures products including dry freight and refrigerated trailers, platform trailers, tank trailers, dry and refrigerated truck bodies, structural composite panels and products, trailer aerodynamic solutions, and specialty food-grade processing equipment.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.